Nicotine replacement therapy is widely used in critically ill smokers and its effect on delirium, mortality and duration of intensive care unit (ICU) admission is unknown. The aims of this review were to determine whether the management of nicotine withdrawal with nicotine replacement therapy reduces delirium, mortality or length of stay in critically ill smokers in ICU. The primary outcome was incidence of author-defined ICU delirium. Secondary outcomes were ICU or hospital mortality, ICU-free days at day 28, and ICU or hospital length of stay. We conducted a systematic review and meta-analysis of the data sources MEDLINE, EMBASE, CINAHL, and the Cochrane Database of Systematic Reviews for randomised controlled trials and observational studies. Clinical trials, observational studies and systematic reviews comparing nicotine replacement therapy with placebo or no treatment were included. Case reports, case series, non-systematic reviews and studies that involved children were excluded. Eight studies were eligible (n=2,636) for inclusion in the data synthesis. In a meta-analysis of observational studies, nicotine replacement therapy was associated with increased delirium (three studies; n=908; I 2 =0%; finite element method: odds ratio 4.03 [95% confidence interval 2.64, 6.15]; P <0.001). There was no difference in ICU mortality (three studies; n=1,309; P=0.10, I 2 =44%; finite element method: odds ratio 0.58; 95% confidence intervals 0.31-1.10) and hospital mortality or 28-day ICU-free days. In the absence of high-quality data, nicotine replacement therapy cannot currently be recommended for routine use to prevent delirium or to reduce hospital or ICU mortality in critically ill smokers.
1
. The World Health Organization reported that approximately one in five of the global adult population are smokers, although the prevalence of some geographical regions could be as high as 48% 2 . In the last decade, the incidence of cigarette smoking has declined in the developed countries whilst the use of electronic cigarettes (e-cigarettes) has increased tremendously from 700,000 in 2012 to over 2,000,000 in 2014 3 . Delirium with a fluctuation in consciousness and cognition is highly prevalent in the intensive care unit (ICU) 4, 5 . Nicotine withdrawal is believed to be associated in ICU patients with higher risk of agitation and delirium, which are strongly predictive of duration of ICU admission and mortality 5 . More than half of ICU smokers experience delirium or agitation, which increase the length of hospital stay and incur significant healthcare costs 6 . The implementation of smoke-free hospitals, along with acute medical or surgical hospitalisation, represents a period of sudden enforced cessation of smoking, which may contribute to nicotine withdrawal symptoms such as agitation, hallucination, anxiety, confusion, insomnia and other central nervous system effects 6, 7 . Although there is no clear causal relationship between delirium and ICU outcomes, there is a great interest in strategies to minimise or prevent the incidence of delirium in critically ill smokers.
Nicotine is a naturally occurring alkaloid and its systemic adverse effects include sympathomimetic activity, increased platelet aggregation and immunomodulation [8] [9] [10] . Nicotine replacement therapy (NRT) is available in oral, inhaled and transdermal formulations 11 . It has been safely used in hospital wards and outpatient clinics to alleviate some of the withdrawal symptoms, while increasing the smoking cessation rate as compared to counselling alone 12 
.
Several studies have investigated the risks and benefits of NRT therapy in critically ill smokers, but the results of these studies have been conflicting [13] [14] [15] [16] [17] [18] . One study suggested increased risk of harm with NRT, potentially mediated by systemic nicotine toxicity leading to increased sympathomimetic activity, high myocardial oxygen demand and coronary vasoconstriction 19 . In addition, the majority of ICU patients are vulnerable to haemodynamic instability, and may have multiple organ failure as compared to patients in hospital wards or outpatient clinics 20 . Thus, the efficacy and safety of NRT in the ICU population remains unclear. The aim of this systematic review and meta-analysis were to determine whether the management of nicotine withdrawal with NRT reduces delirium, mortality, or ICU or hospital stay in critically ill smokers in ICU.
Methods
This review was conducted and reported according to the 'Preferred Reporting Items for Systematic Review and Metaanalysis' (PRISMA) statement 2015 21 . The review protocol was registered on PROSPERO (PROPSERO ID: CRD42015020570). The research questions were formulated using a PICO (population-intervention-control-outcome) approach (eTable 1 online).
Search strategy
Ovid MEDLINE (1946 to 2017 April 10), EMBASE (1974 to 2017 April 10), CINAHL and the Cochrane Database of Systematic Reviews were searched for studies of NRT in critically ill smokers. The search strategy and terms used for MEDLINE and EMBASE are provided in eTable 2. Publications not written in the English language were excluded. The bibliographies of included papers and relevant systematic reviews were hand-searched for additional papers. Experts and authors of papers identified in the search strategy were contacted for additional data as indicated.
Outcomes
The primary outcome was author-defined delirium at any time during ICU stay. Pre-specified secondary outcomes were ICU mortality, hospital mortality and ICU-free days. Other relevant outcomes were considered for the meta-analysis if they were measured in more than one of the included studies. On this basis, ICU and hospital length of stay (LOS) were also included.
Study selection and data extraction
Titles and abstracts were independently screened against eligibility criteria by two authors. The same two reviewers independently screened full texts of qualifying papers. A third reviewer resolved disagreements at any stage. Inclusion criteria were clinical trials, observational studies or systematic reviews that compared the effects of NRT with placebo or no treatment on the outcomes of delirium, mortality, ICU-free days and LOS. Case reports, case series and non-systematic reviews were excluded. Studies involving patients in paediatric intensive care and patients <16 years of age were also excluded. Risk of bias assessment was evaluated using the Newcastle-Ottawa score, which assessed observational studies for methodological quality with up to nine points (or stars), assigned for cohort selection, comparability and data integrity 22 . Randomised controlled trials were assessed using the Cochrane Collaboration Risk of Bias Assessment Tool. In addition to the measures of outcomes, other data fields (citation, country, population [e.g. severe sepsis, trauma, general ICU, mixed ICU] and route of administration of NRT) were extracted.
Statistical analysis
Statistical analyses were undertaken using STATA 11 (StataCorp, College Station, TX) and RevMan Review Manager version 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). Funnel plots were constructed for all primary and secondary outcomes in order to assess the risk of publication bias. Chi-squared bias (χ 2 ) and I 2 tests were used to assess the heterogeneity of studies. The values of 0.25, 0.50 and 0.75 were used to determine low, moderate and high heterogeneity, respectively. A P-value of <0.1 was considered to denote the statistical significance of heterogeneity.
In line with standard methodology, if no significant heterogeneity was noted, a fixed-effect model (FEM) analysis (Mantel-Haenszel method) was used to pool estimates. If evidence of significant heterogeneity was observed, a random-effects model (REM) analysis (DerSimonian-Laird) method was used. Findings were reported as odds ratios (OR) or mean difference (MD) with 95% confidence intervals (CI). 
Results
The results of the literature search and study selection process are outlined in the PRISMA flow chart (Figure 1 previous page). The titles and abstracts of 4,823 nonduplicate articles were screened, of which 17 articles were retrieved. After applying inclusion and exclusion criteria, eight articles with a total of 2,636 subjects were included in this review. A meta-analysis of the observational studies was performed. Details of the excluded studies are outlined in eTable 3 online.
Study characteristics
The characteristics of the included studies are described in Table 1 . One study was a randomised controlled trial (RCT) 23 . The other studies were retrospective observational design 14, 16, 19, [24] [25] [26] and one prospective observational study 13 . Three studies were of a mixed medical/surgical ICU population 16, 23, 26 , two were of a medical ICU population 13, 19 , one was a postoperative coronary artery bypass graft (CABG) population 24 , and two were of a neurosurgical ICU population 14, 25 . None of the studies were commercially sponsored, and there were no declared conflicts of interest.
Funnel plots demonstrated no risk of publication bias for primary and secondary outcomes. Overall, risk of bias in the included studies was low and no studies were excluded on this basis. For the single randomised trial, there was insufficient information given in the manuscript to adequately assess risk of bias, and it was given an 'unclear' rating (eFigures 1-6 online).
Randomised controlled trial
The only RCT identified in this review was a pilot study comparing a 21 mg NRT patch with placebo patch in a mixed medical-surgical ICU setting. This study did not demonstrate any statistically significant differences in duration of mechanical ventilation or ICU LOS.
Meta-analysis of observational studies
The seven observational studies reporting outcomes of interest were included in the meta-analysis.
Primary outcome: ICU delirium
Three studies examined the incidence of delirium at any time during ICU stay-a total of 908 patients 14, 16, 26 . Statistical (Figure 2 ).
Secondary outcomes: ICU and hospital mortality; ICUfree days
Three studies measured mortality at ICU discharge and were included in the meta-analysis, a total of 1,309 patients 13, 14, 16 . Statistical heterogeneity was assessed as moderate. There was no significant difference in ICU mortality between smokers receiving NRT and controls (P=0.10, I 2 = 44%; FEM: OR 0.58; 95% CI 0.31-1.10) (Figure 3 ). Seven studies measured mortality at hospital discharge, a total of 2,548 patients 13, 14, 16, 19, [24] [25] [26] . Statistical heterogeneity was assessed as moderate. Compared to controls, NRT patients showed no difference in hospital mortality (P=0.89, I 2 = 62%; REM: OR 1.04; 95% CI 0.58-1.89) (eFigure 1 online). ICU-free days at day 28 were measured in two studies (n=736) 14, 19 . Statistical heterogeneity was assessed as moderate. Compared to controls, NRT patients showed no difference in ICU-free days (n=736; I 
Additional outcomes: duration of ICU and hospital admission
No statistically significant difference in duration of ICU LOS was detected between NRT and the control group (eFigure 3) in two studies 14, 16 , but hospital LOS was increased in patients who were given NRT in three studies (n=921; I 
Discussion
The main findings of this systematic review and metaanalysis were that NRT administration was associated with increased ICU delirium and length of hospital stay, but not the length of ICU stay. We did not observe any significant effect of NRT on either ICU or hospital mortality. The quality of evidence for NRT use in critically ill patients remained poor. Only one out of the seven observational studies identified by our review was prospective, and we found only one interventional trial which was a small (40 patients), low power, single-centre trial with high risk of bias. The remaining studies were retrospective in design, and it was not possible to control for important confounders in our meta-analysis.
Given that NRT was prescribed to ameliorate nicotine withdrawal and reduce delirium and concomitant sedation, the fact that this analysis found the opposite effect was perplexing. The majority of studies included in this analysis were observational in nature and hence, subject to bias and confounding. Cigarette smoking was associated with increased incidence of alcohol and drug use in another study of 144 critically ill smokers 6 . Therefore, it is possible that patients receiving NRT may also be at increased risk of withdrawal from alcohol and other recreational drugs. In that study, nicotine withdrawal was associated with increased sedation requirements and unplanned removal of tubes and catheters 6 . Thus, those prescribed NRT in the observational trials included in this analysis were at increased risk of delirium from other causes and of increased sedation requirement. Moreover, selection bias may also be an issue in the recruitment process. For instance, NRT may only be prescribed in smokers with existing delirium and sedation difficulties or with concomitant alcohol or drug history rather than routinely to all smokers. This was highlighted as a potential source of confounding in both studies reporting the incidence of delirium 14, 16 . In the only prospective cohort study included in this analysis, those in the control group were more likely to have lesser cigarette consumption and were less likely to be ventilated 13 . Kerr and colleagues suggested that the absorption and distribution of NRT via the transdermal route remains unknown, and that the sympathomimetic effects of nicotine from NRT may further compromise the already complicated physiology of critically ill smokers 26 .
With little data to support the clinical efficacy and safety of NRT, the potential for harm becomes paramount for clinicians considering this therapy for their patients. As outlined above, there were theoretical risks of increased cardiovascular complications associated with NRT treatment. In a retrospective matched cohort study of medical ICU patients included in this analysis, excess hospital mortality in NRT treated patients was reported, raising concerns of potential harm of NRT 19 . The authors of this study speculated that potential causes may include the sympathomimetic effects of nicotine, including hypertension and coronary vasoconstriction 19 . However, subsequent studies failed to replicate this finding even after adjustment for potential confounding 14, 16 . One further study specifically examined adverse vascular events and found no increase in hospital mortality 16 . A recently published retrospective matched casecontrol study found no significant difference in the 30-day mortality rates between NRT and the control group 26 . On the other hand, a study of NRT in cigarette smokers with acute subarachnoid haemorrhage suggested a lower risk of death at 90 days, suggesting a possible protective effect in this patient group 14 . More recent experimental studies proposed that nicotine therapy may have beneficial immunomodulatory effects, including reduction in inflammatory lung injury 27 . Our review was unable to find any significant effects of NRT administration on either ICU or hospital mortality.
Strengths of this review were that it represented a comprehensive up-to-date analysis of studies investigating the role of NRT in ICU patients. An exhaustive literature search was carried out. Authors of previous studies were contacted and some were able to make their data available to us 14, 16 . Included studies were subjected to a rigorous assessment of methodological quality. A previous synthesis of such evidence was conducted in 2011 and included reports of case series and lacked a meta-analysis 13 . A more recent review was conducted in 2014 20 , however our analysis added four further well-conducted cohort studies 19, [24] [25] [26] . The addition of a meta-analysis could provide an estimate of important outcomes across these studies and it would be useful to inform future trials in this area.
Limitations
Limitations of this study were common to other metaanalyses of observational data; namely the non-randomised nature of the data, and the varying strategies adopted by investigators to control for confounding in individual studies. Study subjects were drawn from cardiac, neurosurgical and general critical care populations. Unfortunately, we were not able to control for confounding factors at review level. Despite the evidence of low statistical heterogeneity in the primary outcome, our pooled estimates were unadjusted and should be interpreted with caution. As suggested, the delirium estimates which appeared in the original manuscripts were unadjusted, and thus likely to be heavily biased.
Despite lack of proven benefit, administration of NRT to critically ill smokers continues with the goals of reducing the incidence of ICU delirium and ultimately duration of ICU and hospital admission. Based on this review, there was no evidence to support the routine administration of NRT to critically ill smokers. Equipoise exists for further adequately powered RCTs of NRT in the ICU setting. We found an ongoing RCT, the NicGoWell trial (NCT01362959) that set out to establish the safety and efficacy profile of NRT in critically ill smokers 28 . This study started recruitment in 2011 and randomised 70 patients in total. Given its small sample size, it is unlikely that this study will yield conclusive results. Thus, an adequately powered multicentre RCT would definitely be required to answer this question.
In a meta-analysis of 2,636 critically ill adult smokers in eight studies, NRT therapy was associated with an increased incidence of author-defined delirium and hospital LOS. No significant differences were detected in ICU or hospital mortality or duration of ICU admission. Due to the observational nature of most of the included data, these estimates were at risk of bias and confounding. Despite the widespread use of NRT, there was insufficient evidence to make recommendations regarding benefit or harm associated with using NRT in critically ill smokers. At present, the benefits and risks of administrating NRT require clinical judgement on an individual basis. A large RCT would be required to demonstrate the safety profile of the utilisation of this therapy in the adult smoker in ICU setting.
